High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center

[1] Aboueshia M(2021)Cancer and COVID-19: analysis of patient outcomes Future Oncol 17 3499-3510

[2] Hussein MH(2021)Clinical characteristics and predictors of 28-day mortality in 352 critically Ill patients with COVID-19: a retrospective study J Epidemiol Glob Health 11 98-104

[3] Attia AS(2021)Sex-based differences in severity and mortality in COVID-19 Rev Med Virol 31 30-36

[4] Swinford A(2021)Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients Clin Exp Rheumatol 39 288-296

[5] Miller P(2021)Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study Int J Infect Dis 103 561-566.e564

[6] Omar M(2020)The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis Pediatr Blood Cancer 67 e325-e331

[7] Alharthy A(2021)Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study J Allergy Clin Immunol 147 e253-e261

[8] Aletreby W(2020)Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Lancet Rheumatol 2 3720-3732

[9] Faqihi F(2021)Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study Lancet Rheumatol 3 74-79

[10] Balhamar A(2011)Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Blood 117 773-779

[1] Aboueshia M(2021)Cancer and COVID-19: analysis of patient outcomes Future Oncol 17 3499-3510

[2] Hussein MH(2021)Clinical characteristics and predictors of 28-day mortality in 352 critically Ill patients with COVID-19: a retrospective study J Epidemiol Glob Health 11 98-104

[3] Attia AS(2021)Sex-based differences in severity and mortality in COVID-19 Rev Med Virol 31 30-36

[4] Swinford A(2021)Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients Clin Exp Rheumatol 39 288-296

[5] Miller P(2021)Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study Int J Infect Dis 103 561-566.e564

[6] Omar M(2020)The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis Pediatr Blood Cancer 67 e325-e331

[7] Alharthy A(2021)Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study J Allergy Clin Immunol 147 e253-e261

[8] Aletreby W(2020)Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Lancet Rheumatol 2 3720-3732

[9] Faqihi F(2021)Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study Lancet Rheumatol 3 74-79

[10] Balhamar A(2011)Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Blood 117 773-779